Fibromyalgia

Tonix Pharmaceuticals Announces Two Poster Presentations of TNX-102 SL (Sublingual Cyclobenzaprine HCl) at the ASCP Annual Meeting

Retrieved on: 
torsdag, maj 30, 2024
NDA, FDA, Trauma, Reduction, PTSD, ASD, Week, COVID, ASCP, Therapy, Disability, Infection, Cocaine, Psychiatry, New Drug Application, Sleep, Sumatriptan, ASR, Autoimmunity, CNS, OASIS, Security (finance), Tonix Pharmaceuticals, Military personnel, Insomnia, Food, Safety, Long, Research, Cancer, Fatigue, Annual report, PROMIS, Society, Cognition, Failure, Science, Fibromyalgia, Patient, Risk, Government, Breakthrough therapy, CD40L, Health, Acute stress disorder, Observation, Veteran, Central nervous system, Disease, Annual general meeting, Pharmaceutical industry

CHATHAM, N.J., May 30, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced two poster presentations at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting being held May 28-31, 2024 in Miami Beach, Fla. Copies of the presentations are available under the Scientific Presentations tab of the Tonix website at www.tonixpharma.com.

Key Points: 
  • Copies of the presentations are available under the Scientific Presentations tab of the Tonix website at www.tonixpharma.com .
  • TNX-102 SL was well tolerated with an adverse event profile comparable to prior studies and no new safety signals observed.
  • Previous trials of TNX-102 SL showed that it reduced military PTSD symptoms in as early as two weeks with favorable tolerability.
  • Randomized clinical trial of bedtime sublingual cyclobenzaprine (TNX-102 SL) in military-related PTSD and the role of sleep quality in treatment response.

Tonix Pharmaceuticals Announces Two Oral Presentations and One Poster Presentation Involving TNX-1500 (Fc-modified humanized anti-CD40L mAb) at the American Transplant Congress 2024

Retrieved on: 
onsdag, maj 29, 2024
Security (finance), Sumatriptan, Risk, Food, NDA, FDA, Autoimmunity, Government, Breakthrough therapy, Long, CD40L, Research, Cancer, Fibromyalgia, CNS, Annual report, Therapy, Infection, Failure, Central nervous system, Cocaine, Disease, Pharmaceutical industry

TNX-102 SL is also being developed to treat acute stress reaction as well as fibromyalgia-type Long COVID.

Key Points: 
  • TNX-102 SL is also being developed to treat acute stress reaction as well as fibromyalgia-type Long COVID.
  • Tonix’s CNS portfolio includes TNX-1300 (cocaine esterase), a biologic designed to treat cocaine intoxication that has Breakthrough Therapy designation.
  • Tonix also has product candidates in development in the areas of rare disease and infectious disease.
  • All of Tonix's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements.

Aviv Clinics Spotlights New Study Using Hyperbaric Oxygen Therapy for Adults Suffering from Fibromyalgia Related to Childhood Sexual Abuse

Retrieved on: 
tisdag, maj 28, 2024
FMS, Patient, Syndrome, Hyperbaric medicine, Shamir Medical Center, Trauma, HBOT, PTSD, Stroke, Health, CSA, DSM-IV codes, Traumatic brain injury, COVID, Fatigue, Brain, Research, Injury, Environment, Quality of life, History, Oxygen, Fibromyalgia, Physical abuse, Pharmaceutical industry

The report, Hyperbaric oxygen therapy vs. pharmacological intervention in adults with fibromyalgia related to childhood sexual abuse: prospective, randomized clinical trial , was conducted by the Sagol Center for Hyperbaric Medicine and Research at Shamir Medical Center and published in the peer-reviewed journal of Nature’s Scientific Reports.

Key Points: 
  • The report, Hyperbaric oxygen therapy vs. pharmacological intervention in adults with fibromyalgia related to childhood sexual abuse: prospective, randomized clinical trial , was conducted by the Sagol Center for Hyperbaric Medicine and Research at Shamir Medical Center and published in the peer-reviewed journal of Nature’s Scientific Reports.
  • Fibromyalgia syndrome (FMS) is a debilitating condition characterized by chronic widespread pain, along with symptoms of fatigue, disrupted sleep, and cognitive dysfunction.
  • Among these triggers, traumatic experiences, including childhood sexual, emotional, or physical abuse, have been suggested as predisposing factors in a substantial number of FMS patients.
  • The Aviv Medical Program includes an in-depth assessment of the patient’s physical and neurological condition to assess their overall health.

Virios Therapeutics Announces Closing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study

Retrieved on: 
onsdag, maj 22, 2024
Form S-3, Conditional sentence, Therapy, Telephone, Sale, Form, Prospectus, Attention, Fibromyalgia

Gross proceeds from the offering are $1.7 million before deducting placement agent fees and offering expenses.

Key Points: 
  • Gross proceeds from the offering are $1.7 million before deducting placement agent fees and offering expenses.
  • Virios Therapeutics intends to use the net proceeds of the offering to commence preparatory activities for its planned IMC-2 Long-COVID Phase 2b study and for general corporate purposes.
  • Maxim Group LLC acted as sole placement agent, on a reasonable best-efforts basis, for the offering.
  • The public offering was made pursuant to an effective shelf registration statement on Form S-3, (File No.

Tonix Pharmaceuticals Announces Key Findings from Initial Phase of EVERSANA Market Opportunity Analysis for Tonmya™ for the Management of Fibromyalgia

Retrieved on: 
tisdag, maj 21, 2024
Patient, Hydrogen chloride, Tonix Pharmaceuticals, Polypharmacy, Medicare, Food, NDA, Prevalence, GTM, Diagnosis, FDA, Inflation, Database, Research, Physician, Tablet, Fatigue, Fibromyalgia, Female, Pharmaceutical industry

Tonix previously announced that EVERSANA was selected to support the launch strategy and commercial planning of Tonmya.

Key Points: 
  • Tonix previously announced that EVERSANA was selected to support the launch strategy and commercial planning of Tonmya.
  • Specifically, EVERSANA is working with Tonix to assess the fibromyalgia landscape and help plan an efficient go-to-market (GTM) strategy.
  • “The primary research and analysis conducted by EVERSANA provides valuable insights and informs the vision for the commercialization of Tonmya,” said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals.
  • Key findings from claims data analyses2:
    ~2.7 million adults in the U.S. currently diagnosed and treated for fibromyalgia.

Virios Therapeutics Announces Pricing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study

Retrieved on: 
måndag, maj 20, 2024
Form S-3, Conditional sentence, Therapy, Telephone, Sale, Form, Prospectus, Fibromyalgia, Attention

Gross proceeds from the offering are expected to be approximately $1.7 million before deducting placement agent fees and estimated offering expenses.

Key Points: 
  • Gross proceeds from the offering are expected to be approximately $1.7 million before deducting placement agent fees and estimated offering expenses.
  • The offering is expected to close on May 22, 2024, subject to customary closing conditions.
  • Virios Therapeutics intends to use the net proceeds of the proposed offering to commence preparatory activities for its planned IMC-2 Long-COVID Phase 2b study and for general corporate purposes.
  • A preliminary prospectus supplement and the accompanying prospectus relating to and describing the terms of the public offering have been filed with the SEC.

Virios Therapeutics Announces Proposed Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study

Retrieved on: 
fredag, maj 17, 2024
Form S-3, Conditional sentence, Therapy, Telephone, Sale, Form, Prospectus, Fibromyalgia, Attention

All shares of common stock in the offering are to be offered by Virios Therapeutics.

Key Points: 
  • All shares of common stock in the offering are to be offered by Virios Therapeutics.
  • Virios Therapeutics intends to use the net proceeds of the proposed offering to commence preparatory activities for its planned IMC-2 Long-COVID Phase 2b study and for general corporate purposes.
  • Maxim Group LLC is acting as sole placement agent, on a reasonable best-efforts basis, for the proposed offering.
  • The public offering is being made pursuant to an effective shelf registration statement on Form S-3, (File No.

NeuroMetrix Reports Q1 2024 Business Highlights

Retrieved on: 
onsdag, maj 15, 2024
Patient, Prescription, CMS, Medicare, Hayashi, Absorption, Fibromyalgia, EKG, Peripheral neuropathy, DSM-IV codes, Environment, Pharmaceutical industry

WOBURN, Mass., May 15, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended March 31, 2024.

Key Points: 
  • WOBURN, Mass., May 15, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended March 31, 2024.
  • Revenue in Q1 2024 of $1.1 million was lower by $0.6 million or 37% from Q1, 2023 primarily due to reduced sales volume for DPNCheck.
  • Operating expenses were $3.8 million in Q1 2024, an increase of $0.9 million from the comparable period in 2023.
  • The Q1 2024 net loss was $3.0 million ($1.67 per share) versus a net loss of $1.6 million ($1.64 per share) in Q1 2023.

Tonix Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company Showcase

Retrieved on: 
onsdag, maj 15, 2024
Security (finance), Sumatriptan, Risk, Food, NDA, FDA, Autoimmunity, Breakthrough therapy, Government, Long, CD40L, Research, Cancer, Fibromyalgia, CNS, Annual report, Therapy, Infection, Failure, Central nervous system, Cocaine, Disease, Pharmaceutical industry

A replay of the presentation will also be available under the IR Events tab of the Tonix website at www.tonixpharma.com following the event.

Key Points: 
  • A replay of the presentation will also be available under the IR Events tab of the Tonix website at www.tonixpharma.com following the event.
  • Tonix is a fully-integrated biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering.
  • Tonix’s CNS portfolio includes TNX-1300 (cocaine esterase), a biologic designed to treat cocaine intoxication that has Breakthrough Therapy designation.
  • All of Tonix's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements.

Virios Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

Retrieved on: 
torsdag, maj 9, 2024
Conditional sentence, Research, Insurance, Conference, Conference call, Patent, Disease, BHC, Toxicology, Therapy, Fibromyalgia, Valaciclovir, Celecoxib, Famciclovir, Pharmaceutical industry

ATLANTA, May 09, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”) and Long-COVID (“LC”), today announced financial results for the first quarter ended March 31, 2024 and provided a corporate update.

Key Points: 
  • ET -
    ATLANTA, May 09, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”) and Long-COVID (“LC”), today announced financial results for the first quarter ended March 31, 2024 and provided a corporate update.
  • General and administrative expenses for the first quarter of 2024 were $1.0 million, compared to $1.1 million for the first quarter of 2023.
  • The quarter over quarter change was primarily due to a decrease in insurance expenses associated with being a public company.
  • The Company believes it will have sufficient resources to fund operations into the fourth quarter of 2024.